U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07134998) titled 'Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations' on Aug. 14.
Brief Summary: This is an open-label, multi-center phase I clinical study to evaluate HRS-6093 Safety, Tolerability, and Pharmacokinetics in Participants harboring KRAS G12D Mutations with advanced solid tumors. The study consists of dose escalation, dose expansion and efficacy expansion.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Advanced KRAS G12D Mutant Solid Tumors
Intervention:
DRUG: HRS-6093
HRS-6093
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
...